Athira Pharma (ATHA) Stock Explodes 73% Higher on Breakthrough Cancer Drug Deal

BitRSSDecember 18, 2025

AI Summary

AI analysis pending - showing article title

Summary

TLDR Athira Pharma stock jumped 73.4% in premarket trading after acquiring global rights to lasofoxifene, a Phase 3 breast cancer drug targeting ESR1 mutations The company secured an exclusive license from Sermonix Pharmaceuticals for the late-stage treatment currently enrolled...

SEC